Drug intelligence / Profile preview

recombinant anti-human IL12 nanobody

Development stage: Preclinical
Lead developer: Creative BioMart
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Recombinant anti-human IL12 nanobody is a recombinant nanobody designed to target human Interleukin-12 (IL12), a key cytokine involved in immunology and inflammation. Creative BioMart entered into an agreement with an undisclosed U.S. pharmaceutical giant for the supply, collaborative development, and commercialization of this nanobody, aiming to develop novel immunomodulatory therapeutics for inflammatory conditions.

Targets

IL12 (Interleukin-12)

Beyond the preview

Go deeper on recombinant anti-human IL12 nanobody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant anti-human IL12 nanobody.

Explore the full profile